[Clinical studies on gabapentin in Switzerland]

Gabapentin is a new antiepileptic for the combination therapy of partial seizures. It was introduced in January 1995 in Switzerland. This article describes briefly the ongoing clinical studies in Switzerland; meanwhile, these multicenter studies are conducted in different countries. An open study will evaluate the number of seizure-free patients under therapy with different dosages of gabapentin as add-on therapy. The efficacy and tolerance of gabapentin will be compared with carbamazepine as monotherapy. The last study examines the efficacy of gabapentin for the treatment of partial seizures in pediatric population.